{
  "docId": "019de073-948a-7043-8b3b-a5ac9bb504f9",
  "docSlug": "d72f38beef66cb68e946399178678a94",
  "documentTitle": "Roivant Sciences | Investor Presentation Deck | 21 slides",
  "authorId": "roivant-sciences",
  "authorName": "Immunovant",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 21,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Includes financial runway disclosure in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-948a-7043-8b3b-a5ac9bb504f9/12",
  "deckHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9",
  "deckJsonHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9.json",
  "deckAnchorHref": "/decks/019de073-948a-7043-8b3b-a5ac9bb504f9#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Ongoing in-house development; GMP drug product manufacture completed; 6-week nonclinical studies completing shortly with IND filing planned in early 2023; Initial Phase 1 data expected in mid-2023; IMVT-1402 development activities included in cash runway guidance into 2025",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9e5df9f-148d-41cf-b3d8-242fb8b0daa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.28,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. The assumptions upon which we have based our estimates, including expenditures relating to planned or potential clinical trials, are routinely evaluated and may be subject to change. 2. As of September 22, 2022, our cash balance was approximately $410M, and our cash burn for the period from July 1, 2022 to September 22, 2022 was approximately $17M",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9137d733-72c7-4820-9a22-8fec88534b91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.75,
        "y": 0.35
      },
      "kind": "image",
      "text": "IMVT-1402 antibody illustration",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c02e8b41-c7fa-4595-a905-21a9a779f7f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.75,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Novel, fully human, monoclonal antibody inhibiting FcRn-mediated recycling of IgG",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f18820-1f88-4e7b-b904-e6fb98bda7bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "IMVT-1402 development is well underway, with initial Phase 1 data expected in mid-2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c27bdd5e-5a65-4e93-8689-36cf4bf56681",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "f51c512a-07c6-4da7-8943-3e26e3685a4f",
      "evidence": "Sequential development milestones presented as a vertical process flow.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}